Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.

Frontiers in immunology（2022）

引用 0|浏览4

暂无评分

摘要

ClinicalTrials.gov number, NCT04666168.

查看译文

关键词

BTK inhibitor,CD19 CAR-T cell therapy,PD-1 antibody,scnsl,tislelizumab,zanubrutinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要